Nov 17, 2025

Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity

This Strategic Transaction Expands Azurity’s Existing Gastrointestinal Portfolio

Woburn, MA – November 17, 2025 – Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies.

Ronald Scarboro, CEO of Azurity Pharmaceuticals said: “We are pleased to welcome Sebela Pharmaceuticals’ GI team and product portfolio to Azurity. This strategic acquisition aligns with our long-term growth priorities by strengthening our presence in Gastroenterology and further diversifying our portfolio of medicines. We look forward to building on Sebela’s strong heritage of innovation in gastroenterology and continuing to deliver meaningful value to patients, healthcare providers, and our partners.”

Alan Cooke, President and CEO of Sebela Pharmaceuticals said: “Azurity Pharmaceuticals will be a strong and strategic home for our bowel prep franchise and the talented commercial team supporting it. We wish the Azurity team continued success with these innovative brands. At Sebela, we will continue to lead the way in the development of a new treatment for gastroesophageal reflux disease (GERD) and are excited about the potential of tegoprazan, our novel therapy, as we prepare to submit a new drug application to the FDA this quarter.”

The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States.

With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams. Azurity and Sebela Pharmaceuticals will work closely to ensure a smooth transition for employees, customers, and partners.

Barclays served as financial advisor and Eversheds Sutherland served as legal advisor to Azurity. Jefferies served as financial advisor and Mayer Brown served as legal advisor to Sebela for this transaction.

About Sebela Pharmaceuticals:

At Sebela Pharmaceuticals we are building a leading gastroenterology company in the US and developing innovative products in women’s health. Braintree Laboratories, Inc, a part of Sebela Pharmaceuticals, has been innovating, developing, manufacturing and commercializing gastroenterology products for over 40 years. Braintree’s lead program is tegoprazan, a novel potassium competitive acid blocker (PCAB) which has completed its Phase 3 program in gastroesophageal reflux disease (GERD), specifically, erosive esophagitis (EE) and non-erosive reflux disease (NERD). For more information, visit www.sebelapharma.com.

About Azurity Pharmaceuticals:

Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ marketed brands spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. For more information, visit www.azurity.com.

Disclosure notice: Azurity and Sebela undertake no obligation to update or revise any forward-looking statements contained in this release as a result of new information, future events, or evolving circumstances.

Contacts:

Back to News and Events
Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Show details Hide details
Functional and Performance Cookies

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Show details Hide details
Targeting Technologies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Show details Hide details
Powered by  GDPR Cookie Compliance